Tralokinumab Achieves Primary and Secondary Endpoints in Three Pivotal Phase 3 Trials in Adult Patients with Moderate-to-Severe Atopic Dermatitis!

Tralokinumab Achieves Primary and Secondary Endpoints in Three Pivotal Phase 3 Trials in Adult Patients with Moderate-to-Severe Atopic Dermatitis!

Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13,[1] and is designed for the treatment of asthma and other inflammatory diseases.[2] Tralokinumab was discovered by Cambridge Antibody Technology scientists, using Ribosome Display, as CAT-354[3] and taken through pre-clinical and early clinical development.[4] After 2007 it has been developed by MedImmune, a member of the AstraZeneca group, where it is currently in Ph3 testing for asthma and Ph2b testing for atopic dermatitis.[5][6] This makes it one of the few fully internally discovered and developed drug candidates in AstraZeneca’s late stage development pipeline.https://www.drugs.com/clinical_trials/tralokinumab-achieves-primary-secondary-endpoints-three-pivotal-phase-3-trials-adult-patients-18672.html?utm_source=ddc

PharmahubNG

Welcome to Pharmahub!